Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Makes Oncology Debut With Halaven, But Development Question Marks Remain

This article was originally published in The Pink Sheet Daily

Executive Summary

Already in the small minority of drugs to gain approval via overall survival, Eisai's ability to gain additional indications for Halaven may hinge on improving the drug's progression-free survival data.
Advertisement

Related Content

Eisai Will Try For Halaven Label Expansion, Despite Phase III Failure
Eisai Will Try For Halaven Label Expansion, Despite Phase III Failure
Nektar Readies Phase III Breast Cancer Trial Of NKTR-102, On Its Own
Nektar Readies Phase III Breast Cancer Trial Of NKTR-102, On Its Own
Pediatric Oncology Panel Highlights Trend Toward Being More Selective With Studies
Pediatric Oncology Panel Highlights Trend Toward Being More Selective With Studies
FDA Official Stresses "Flexibility" On Speeding Approval Of Drugs That Truly Stand Out
FDA Official Stresses "Flexibility" On Speeding Approval Of Drugs That Truly Stand Out
Eisai And Pfizer Begin Undertaking To Switch Appropriate Patients To High-dose Aricept

Topics

Advertisement
UsernamePublicRestriction

Register

PS071449

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel